Ensysce Biosciences, Inc. (ENSC) Insider Trading Activity

NASDAQ$0.3674-0.01 (-2.65%)
Market Cap
$7.35M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
182 of 849
Rank in Industry
106 of 491

ENSC Insider Trading Activity

ENSC Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$444,169
2
100
Sells
$0
0
0

Related Transactions

GOWER BOB Gdirector
2
$444,169
0
$0
$444,169

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced …

Insider Activity of Ensysce Biosciences, Inc.

Over the last 12 months, insiders at Ensysce Biosciences, Inc. have bought $444,169 and sold $0 worth of Ensysce Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Ensysce Biosciences, Inc. have bought $394,941 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: GOWER BOB G (director) — $444,169.

The last purchase of 400,000 shares for transaction amount of $198,000 was made by GOWER BOB G (director) on 2026‑08‑07.

List of Insider Buy and Sell Transactions, Ensysce Biosciences, Inc.

2026-08-07PurchaseGOWER BOB Gdirector
400,000
5.5652%
$0.49
$198,000
-17.45%
2026-04-23PurchaseGOWER BOB Gdirector
508,614
6.2578%
$0.48
$246,169
-10.91%
2023-03-02PurchaseGOWER BOB Gdirector
90,287
0.6576%
$0.49
$44,087
-71.07%
2023-03-01PurchaseGOWER BOB Gdirector
270,000
2.1241%
$0.48
$128,979
-68.06%
2023-02-28PurchaseGOWER BOB Gdirector
109,300
0.8628%
$0.49
$53,371
-68.47%
2022-12-09PurchaseGOWER BOB Gdirector
357,143
19.2974%
$1.40
$500,000
-83.82%
2022-05-25PurchaseKirkpatrick LynnChief Executive Officer
27,000
0.0797%
$0.53
$14,216
-78.38%
2020-06-19SaleMORGAN STANLEY10 percent owner
776,290
0.2223%
$10.44
$8.1M
-4.82%
2017-12-01PurchaseHG Vora Capital Management, LLC10 percent owner
1M
4.2688%
$10.00
$10M
Total: 9
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
GOWER BOB Gdirector
916740
4.7117%
$346,252.7060
<0.0001%
HG Vora Capital Management, LLC10 percent owner
3837500
19.7232%
$1.45M10
Kirkpatrick LynnChief Executive Officer
381851
1.9626%
$144,225.1210
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$13,664,154
40
-70.35%
$7.05M
$29,645,465
28
8.09%
$6.48M
$63,749,694
24
-12.24%
$6.4M
$287,718
15
-41.45%
$5.68M
$812,698
12
-57.09%
$7.89M

ENSC Institutional Investors: Active Positions

Increased Positions12+75%206,905+58.83%
Decreased Positions6-37.5%55,984-15.92%
New Positions5New87,987New
Sold Out Positions5Sold Out55,284Sold Out
Total Postitions22+37.5%502,620+42.91%

ENSC Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Perceptive Advisors Llc$81.002.17%86,66600%2025-09-30
Adage Capital Partners Gp, L.L.C.$70.001.87%74,71100%2025-09-30
Drw Securities, Llc$65.001.73%69,145+69,145New2025-09-30
Vanguard Group Inc$35.000.92%36,708+36,708New2025-09-30
Renaissance Technologies Llc$15.000.39%15,574+15,574New2025-09-30
Citadel Advisors Llc$14.000.36%14,518+14,518New2025-09-30
Virtu Financial Llc$13.000.36%14,222+14,222New2025-09-30
Geode Capital Management, Llc$12.000.33%13,030+2,869+28.23%2025-09-30
Xtx Topco Ltd$10.000.27%10,957+10,957New2025-09-30
Tru Independence Asset Management 2, Llc$10.000.26%10,500+10,500New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.